Haemonetics Corp key statistics and ratios

In fiscal 2026, Haemonetics Corp had return on equity of 12.0%, an operating margin of 11.7%, debt equal to 155.7% of equity and a current ratio of 2.95. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Haemonetics Corp: financial ratios, annual
Fiscal year	2010Apr 2010	2011Apr 2011	2012Mar 2012	2013Mar 2013	2014Mar 2014	2015Mar 2015	2016Apr 2016	2017Apr 2017	2018Mar 2018	2019Mar 2019	2020Mar 2020	2021Apr 2021	2022Apr 2022	2023Apr 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026	LTMJun 2026
Gross margin	52.3%	52.5%	50.7%	48.0%	49.9%	47.7%	44.7%	42.7%	45.6%	43.2%	49.0%	45.7%	50.9%	52.6%	52.8%	55.0%	59.0%	59.0%
Operating margin	12.9%	16.3%	12.2%	6.3%	4.9%	4.5%	−4.8%	−2.2%	6.2%	8.6%	10.5%	10.3%	8.1%	13.4%	12.6%	16.3%	11.7%	11.9%
Net margin	9.0%	11.8%	9.2%	4.3%	3.7%	1.9%	−6.1%	−3.0%	5.0%	5.7%	7.7%	9.1%	4.4%	9.9%	9.0%	12.3%	7.3%	7.1%
Free-cash-flow margin	11.5%	11.3%	8.5%	2.6%	7.0%	0.5%	2.1%	9.4%	16.1%	4.2%	11.1%	8.2%	7.6%	7.0%	11.0%	10.5%	19.5%	21.5%
Return on equity	9.8%	12.5%	9.4%	5.2%	4.4%	2.0%	−7.2%	−3.6%	6.1%	7.7%	12.2%	12.1%	5.9%	14.7%	13.2%	18.8%	12.0%	11.8%
Return on assets	7.6%	10.0%	7.7%	3.3%	2.4%	1.1%	−4.0%	−2.1%	3.7%	4.4%	6.0%	5.1%	2.4%	6.1%	5.7%	7.2%	4.0%	4.0%
Asset turnover	0.84	0.85	0.83	0.75	0.63	0.61	0.65	0.69	0.73	0.77	0.78	0.56	0.54	0.62	0.63	0.59	0.55	0.57
Current ratio	2.86	4.13	4.03	3.31	2.87	2.96	2.63	2.42	1.35	2.44	2.20	2.74	1.71	3.06	2.56	1.62	2.95	3.08
Debt to equity	3.5%	0.7%	0.5%	63.1%	52.5%	52.1%	56.6%	42.7%	33.7%	52.4%	65.1%	96.7%	103.2%	93.6%	84.1%	149.2%	155.7%	141.9%
Interest cover (operating income ÷ interest)	112.2x	—	—	—	—	—	—	—	7.3x	6.6x	7.7x	9.5x	13.9x	12.0x	8.5x	6.2x	8.1x	—
Effective tax rate	28.2%	27.3%	25.3%	22.2%	3.4%	45.8%	—	—	23.6%	25.3%	12.2%	−9.0%	31.8%	18.4%	22.6%	20.9%	24.0%	26.2%
R&D as % of revenue	4.1%	4.8%	5.1%	5.0%	5.8%	6.0%	4.9%	4.2%	4.3%	3.7%	3.1%	3.8%	4.7%	4.3%	4.2%	4.6%	4.5%	4.4%
SG&A as % of revenue	33.2%	31.6%	33.5%	36.2%	39.0%	37.0%	34.9%	34.1%	35.0%	28.3%	28.5%	31.6%	34.2%	32.2%	32.8%	32.1%	33.2%	33.3%
Capital spending as % of revenue	8.7%	6.9%	7.3%	7.0%	7.8%	13.4%	11.3%	8.6%	8.3%	12.3%	4.9%	4.3%	9.7%	16.4%	2.9%	2.9%	2.5%	2.7%
Free cash flow ÷ net income	127.4%	96.0%	92.9%	59.0%	187.4%	29.3%	—	—	319.4%	73.3%	143.0%	90.3%	174.6%	70.8%	122.2%	85.0%	267.6%	302.4%
Dividends and buybacks ÷ free cash flow	53.8%	65.1%	80.5%	218.5%	0.0%	787.3%	313.4%	0.0%	68.7%	396.8%	159.9%	0.0%	0.0%	91.8%	0.0%	158.0%	67.2%	—

US$ thousands unless shown otherwise. Fiscal quarters.

Haemonetics Corp: financial ratios, quarterly
Quarter	2025 Q2Sept 2024	2025 Q3Dec 2024	2025 Q4Mar 2025	2026 Q1Jun 2025	2026 Q2Sept 2025	2026 Q3Dec 2025	2026 Q4Mar 2026	2027 Q1Jun 2026
Gross margin	54.2%	55.5%	58.4%	59.8%	59.5%	59.7%	57.2%	59.8%
Operating margin	15.0%	16.9%	21.6%	16.8%	17.9%	19.9%	−6.6%	16.9%
Net margin	9.8%	10.8%	17.5%	10.6%	11.8%	13.2%	−5.8%	9.7%
Free-cash-flow margin	11.4%	10.1%	30.5%	4.2%	32.5%	25.7%	15.4%	13.1%
Current ratio	3.49	3.97	1.62	1.72	1.64	1.75	2.95	3.08
Debt to equity	139.4%	135.1%	149.2%	138.8%	144.2%	134.4%	153.8%	140.3%
R&D as % of revenue	4.1%	4.5%	5.5%	5.1%	4.5%	4.2%	4.2%	4.8%
SG&A as % of revenue	31.0%	30.5%	34.8%	34.4%	31.0%	32.2%	34.9%	35.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 5 checks passed · June 27, 2026

What it owns · $2.4bn

Short-term assets $811mLonger-term assets $1.6bn

What it owes, and who funded it · $1.1bn

Short-term liabilities $263mShareholders' equity $837m

Short-term assets cover short-term liabilities $811m of assets due within a year against $263m of liabilities due within a year.
Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
More cash than debt $223m of cash against $1.2bn of debt.
Debt below 40% of shareholders' equity Debt is 140% of equity.
Debt burden no higher than five years ago Debt to equity moved from 87% to 140% over five years.
A year's operating cash flow covers at least 20% of debt $328m of operating cash flow against $1.2bn of debt.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Haemonetics Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

62 /100

Moderate moat

How hard Haemonetics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 11 / 20

Cash operating profit has been a median 9.0% of total assets over 10 years.
Pricing power 14 / 20

Gross margin has been a median 50.5%, moving by 5.2 percentage points (standard deviation) across 10 years.
Durability 3 / 20

Operating margin has been a median 11.0%; its worst year was 0.6%.
Cash conversion 15 / 20

Free cash flow was positive in 10 of 10 years, at a median 9.9% of revenue.
Discipline 19 / 20

The diluted share count fell 8.8% over five years; stock-based pay has been a median 2.2% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: HAE vs STVN HAE vs PEN HAE vs MMSI

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Haemonetics Corp's SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Haemonetics Corp.